(Q48906242)

16 February 2018

title

Immunological and clinical consequences of treating a patient with natalizumab. (English)

1 reference

16 February 2018

1 reference

1 reference

1

1 reference

16 February 2018

Renaud Du Pasquier

7

1 reference

16 February 2018

Heinz Wiendl

12

object named as

Heinz Wiendl

1 reference

16 February 2018

8

Ralf Gold

1 reference

16 February 2018

Richard M Ransohoff

10

object named as

Richard M Ransohoff

1 reference

16 February 2018

Sven G Meuth

9

object named as

Sven G Meuth

1 reference

16 February 2018

author name string

Karin G Höhn

2

1 reference

16 February 2018

Tilman Schneider-Hohendorf

3

1 reference

16 February 2018

Imke Metz

4

1 reference

16 February 2018

Max-Philipp Stenner

5

1 reference

16 February 2018

Samantha Jilek

6

1 reference

16 February 2018

Wolfgang Brück

11

1 reference

16 February 2018

publication date

9 September 2011

1 reference

16 February 2018

Multiple Sclerosis Journal

published in

1 reference

16 February 2018

volume

18

1 reference

16 February 2018

issue

3

1 reference

16 February 2018

page(s)

335-344

1 reference

16 February 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Effects of natalizumab treatment on Foxp3+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Alpha4 integrins and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421919

21 January 2018

Identifiers

DOI

10.1177/1352458511421919

1 reference

16 February 2018

1 reference

16 February 2018